Clinton Increases Funding for HIV Research, Relief

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 1
Volume 8
Issue 1

WASHINGTON-As part of World AIDS Day 1998 (December1), President Clinton announced that the federal government will spend $200 million to fund research aimed at developing an effective HIV vaccine during fiscal year 1999. The money represents a 33% increase in AIDS vaccine funding over fiscal year 1998.

WASHINGTON—As part of World AIDS Day 1998 (December1), President Clinton announced that the federal government will spend $200 million to fund research aimed at developing an effective HIV vaccine during fiscal year 1999. The money represents a 33% increase in AIDS vaccine funding over fiscal year 1998.

Another $164 million will be devoted to “other new research critical to fighting AIDS around the world,” the President said. These efforts include a new prevention trials network to reduce adult and peri-natal transmission of HIV; new strategies to prevent and treat HIV infection in children; efforts to train more foreign scientists to help battle the epidemic; and research on the prevention and treatment of opportunistic infections.

The United States will also put up $10 million in emergency relief funds through the US Agency for International Development to provide support to AIDS orphans abroad. Mr. Clinton also directed Sandra Thurman, his AIDS policy advisor, to undertake a fact-finding mission to sub-Saharan Africa—“where 90% of the AIDS orphans live”—and to make recommendations on how to address the problem.

Also, Vice President Al Gore announced that the federal government will provide $220 million in grants for housing and support services for more than 65,000 low-income people infected with HIV and members of their households. The money will be distributed by the Department of Housing and Urban Development under its new Housing Opportunities for Persons With AIDS program.

Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content